Certificate Course in Health Technology Assessment (HTA)

European HTA agencies increasingly integrate AI into evaluations, with Nice leading policy and pilots; others align with EU joint assessments, emphasizing transparency, validation, and human oversight.

Explore how health technology assessment consolidates clinical data, economic evaluations, and social considerations to guide funding, reimbursement, and ethical decisions for healthcare interventions.

Trace the evolution of health technology assessment from anecdote to evidence based practice, highlighting cost effectiveness, real world data, stakeholder engagement, and transparent decision making.

Explore how health technology assessment differs across systems by examining NICE, CADTH, IQWiG, and Australia, France, Sweden, highlighting systematic reviews, cost effectiveness, and stakeholder engagement to guide coverage.

Explore the structure and process of health technology assessment reports, from executive summaries to methods and conclusions, plus standards like prisma and cheers that ensure transparent, actionable recommendations.

Health technology assessment guides adoption, funding, and reevaluation by balancing clinical effectiveness with cost effectiveness, ethics, and stakeholder input, linking macro to micro level decisions through transparent evidence.

Explore how ethics grounds every HTA step, from topic selection to implementation, emphasizing beneficence, justice, autonomy, transparency, and stakeholder engagement to ensure equitable, accountable decisions.

Explore how systematic reviews and meta analyses underpin health technology assessment by framing questions, minimizing bias, synthesizing evidence, and guiding policy decisions through transparent protocols.

Master advanced searching techniques and evidence management for health technology assessments, using proximity operators, field specific queries, and grey literature to build comprehensive, auditable reviews.

Design and conduct a systematic review for health technology assessment using an Osteostrong case to craft questions, perform searches, extract data, assess bias, and inform policy.

Examine how randomized controlled trials and observational studies inform health technology assessment, balancing internal validity, bias considerations, and real-world applicability to guide patient outcomes and policy decisions.

Integrate real world evidence (RWE) with HTA to reflect everyday patient experiences and diverse care. Use real world data sources—EHR, claims, registries, wearables—and pragmatic trials with target trial emulation.

Explore how economic evaluation guides healthcare decisions by comparing costs and outcomes across interventions. Learn how methods like cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis inform HTA and policy.

Explore how health economics guides decisions by weighing outcomes and costs. Include direct, indirect, intangible costs, opportunity cost, cost effectiveness, efficiency, and perspectives.

Assess health related quality of life (HRQoL) and its measurement tools, applying HRQoL data in health economics, HTA, and cost-utility analyses with QALYs to guide chronic disease and palliative care.

Explore health utilities to quantify quality of life and guide cost utility analysis and HTA, using SG, TTO, and VAS alongside EC, Sf6, and Hui to derive collies.

Explore the concept of quality adjusted life years (QALYs) and their calculation, applications in cost utility analysis and health technology assessment, and the ethical considerations shaping health care decisions.

Explore how health economic modeling bridges limited clinical data and real-world decisions, using decision trees, Markov and dynamic models to evaluate long-term outcomes, costs, and utilities.

Deepens health technology assessment modeling with advanced concepts like probabilistic sensitivity analysis, microsimulation, and time-to-event methods, while emphasizing calibration, validation, scenario analysis, and transparent reporting.

Identify how clinical outcomes such as mortality, morbidity, biomarkers, imaging, and hospitalizations ground HTA in real patient health changes. Learn how standardized definitions and transparent reporting enable valid, comparable evidence.

Investigate patient-reported outcome measures (PROMs) in HTA, focusing on development, validation, and use. Learn how PROMs capture daily functioning, quality of life, and guide patient-centered decisions.

Assess health related quality of life (HRQoL) in HTA, comparing physical, mental, and social functioning to derive QALYs and inform coverage decisions.

Explore how patient preferences inform HTA through qualitative and quantitative methods, shaping patient engagement, ethics, policy decisions, and patient-centered technology adoption.

Explore budget impact analysis to assess affordability and budget implications of new health technologies over 1–5 years, considering population, uptake, costs, offsets, and decision-making perspectives.

Master budget impact analysis within health technology assessment by linking scope, perspective, and population to uptake, costs, and multi-year scenarios, with sensitivity analyses guiding policy and budgeting decisions.

Walk through a health technology assessment budget impact case study to frame scope, estimate population, model uptake, and compute impacts for glucose reduce versus metformin and sulfonylureas, with sensitivity analyses.

Articulate the rationale and objectives to guide a high-quality HTA design, then draft a protocol detailing research questions, methods, timelines, and dissemination for stakeholders.

Learn how economic evaluations inform health technology assessments by weighing costs, outcomes, and QALYs to produce ICERs and cost-utility results, applying discounting, models, and sensitivity analyses to guide policy decisions.

Critically appraise health technology assessment reports by evaluating validity, results, and applicability, using structured checklists and frameworks to identify bias and ensure evidence informs policy decisions.

Explore essential software, databases, and guidelines used in health technology assessment (HTA) to organize references, build transparent economic models, and report findings with credibility.

Explore how sofosbuvir reshaped hepatitis C treatment through HTA, balancing breakthrough efficacy with budget impact, price negotiations, and managed access across UK and US systems.

Explore how transcatheter aortic valve implantation (tavi) offers a minimally invasive alternative to savr, with adaptive HTA assessing clinical and cost-effectiveness across risk groups.

Assess how HTA guides HPV vaccination, balancing clinical effectiveness, cost effectiveness, herd immunity, and ethical debates about vaccinating adolescents, using dynamic modeling and stakeholder engagement with screening.

Comparative effectiveness research compares existing treatments directly, using head-to-head trials, network meta-analyses, real-world data, and patient preferences to identify the best option for diverse patient groups.

Explore how health technology assessment shapes drug pricing and reimbursement across national systems, comparing the UK, Canada, Australia, Germany, the US and beyond.

Understand how regulatory frameworks and HTA policies determine safety, efficacy, cost effectiveness, budget impact, and reimbursement, guiding market access and coverage decisions.

Explore how health technology assessment guides reimbursement and pricing decisions, balancing cost effectiveness, budget impact, and value-based models with positive and negative lists, conditional coverage, and risk-sharing agreements.

Foster global health technology assessment through cross-border collaboration, reducing duplication, and harmonizing methods to assess clinical and cost effectiveness, supported by HTAI, INR, Eunet, and WHO.